Latest Regulatory Filings News

Orthocell’s nerve repair device Remplir is being adopted in Australia for nerve-sparing prostate cancer surgeries, aiming to reduce erectile dysfunction and urinary incontinence post-operation. This development could significantly expand Remplir’s market reach globally.

Carbonxt Group has successfully closed its non-renounceable pro-rata entitlement offer, issuing over 51 million Loyalty Options and raising approximately $514,000 to support its expansion plans.

Warriedar Resources has received ASIC approval to delay its 2025 AGM until January 2026, allowing time for critical shareholder votes on proposed share option schemes tied to a Capricorn Metals acquisition.

Camplify Holdings has responded to ASX concerns over a delayed director interest notice, revealing internal process failures and promising tighter compliance measures.

News Corporation has completed a $450 million secondary offering of Class B shares by key Murdoch family trusts, alongside a new stockholders agreement that reshapes family voting power and share transfer rights.

Telix Pharmaceuticals has secured FDA agreement on a resubmission plan for its glioma imaging agent TLX101-CDx, aiming for a Q4 2025 filing that includes additional efficacy data. The FDA signals likely expedited review, underscoring the unmet medical need.

Imagion Biosystems has reached key milestones in its MagSense® HER2 breast cancer imaging program, including starting manufacturing for its Phase 2 trial and launching an AI imaging protocol collaboration with Wayne State University.

Orthocell Limited reports an 81.1% overall treatment success rate from its Remplir Real World Evidence study, reinforcing the product’s safety and efficacy as it expands sales in the US and prepares regulatory submissions for the EU and UK.

The Australian Taxation Office has issued a binding ruling detailing the capital gains tax treatment for Spartan Resources shareholders following Ramelius Resources' acquisition via a Scheme of Arrangement. Eligible shareholders can elect partial scrip-for-scrip rollover relief, deferring tax on the share component of their proceeds.

Cambium Bio has secured a strategic partnership with French pharmaceutical leader Benta SAS to commercialise its regenerative dry eye treatment, Elate Ocular, across Europe and the Middle East. This follows a second platelet-lysate licensing deal within days, underscoring growing industry confidence in Cambium’s platform.

Xamble Group Limited’s XGLO securities have been suspended from trading pending compliance with ASX listing rules, raising questions about the company’s regulatory standing.

Great Northern Minerals Limited has addressed an ASX query regarding the delayed filing of director interest notices, attributing the lapse to an administrative oversight related to option expiry. The company reassures investors that compliance frameworks remain robust.